Analyst Kyle Mikson CFA from Canaccord Genuity maintained a Buy rating on Quanterix and keeping the price target at $12.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Kyle Mikson CFA has given his Buy rating due to a combination of factors that suggest potential for future growth despite current challenges. Quanterix’s recent acquisition of Akoya is seen as a strategic move that could lead to significant synergies over time. The company has outlined a clear plan to integrate Akoya, which includes cost reductions and operational consolidations, aiming for double-digit growth in core markets.
Despite the reported decline in revenue and increased headwinds in the biopharma sector, Quanterix has increased its overall revenue guidance for 2025, driven by the expected contributions from Akoya. The upcoming launch of new products, such as the Simoa One instrument, is anticipated to bolster performance. While the macroeconomic environment presents challenges, the successful execution of these strategic initiatives could enhance Quanterix’s valuation, making the stock an attractive buy.